keyword
https://read.qxmd.com/read/38652584/jfh1-based-core-ns2-genotype-variants-of-hcv-with-genetic-stability-in-vivo-and-in-vitro-important-tools-in-evaluation-of-virus-neutralization
#1
JOURNAL ARTICLE
Laura Collignon, Kenn Holmbeck, Ashley Just, Lieven Verhoye, Rodrigo Velázquez-Moctezuma, Ulrik Fahnøe, Thomas H R Carlsen, Mansun Law, Jannick Prentoe, Troels K H Scheel, Judith M Gottwein, Philip Meuleman, Jens Bukh
BACKGROUND AIMS: HCV infection continues to be a major global health burden, despite effective antiviral treatments. The urgent need for a protective vaccine is hindered by the scarcity of suitable HCV permissive animal models tractable in vaccination and challenge studies. Currently, only antibody neutralization studies in infectious cell culture systems or studies of protection by passive immunization of human-liver chimeric mice offer the possibility to evaluate the effect of vaccine-induced antibodies...
April 23, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38652564/autologous-neutralizing-antibody-responses-after-antiretroviral-therapy-in-acute-and-early-hiv-1
#2
JOURNAL ARTICLE
Gregory D Whitehill, Jaimy Joy, Francesco E Marino, Ryan J Krause, Suvadip Mallick, Hunter M Courtney, Kyewon Park, John W Carey, Rebecca Hoh, Heather Hartig, Vivian Pae, Sannidhi Sarvadhavabhatla, Maria Sophia B Donaire, Steven G Deeks, Rebecca M Lynch, Sulggi A Lee, Katharine J Bar
BACKGROUND: Early antiretroviral therapy initiation (ARTi) in HIV-1 restricts reservoir size and diversity while preserving immune function, potentially improving opportunities for immunotherapeutic cure strategies. For antibody-based cure approaches, the development of autologous neutralizing antibodies (anAb) after acute/early ARTi is relevant, but poorly understood. METHODS: We characterize antibody responses in a cohort of 23 participants following ARTi in acute HIV (<60 days after infection) and early HIV (60-128 days after infection)...
April 23, 2024: Journal of Clinical Investigation
https://read.qxmd.com/read/38651408/beyond-bnabs-uses-risks-and-opportunities-for-therapeutic-application-of-non-neutralising-antibodies-in-viral-infection
#3
REVIEW
Kahlio Mader, Lynn B Dustin
The vast majority of antibodies generated against a virus will be non-neutralising. However, this does not denote an absence of protective capacity. Yet, within the field, there is typically a large focus on antibodies capable of directly blocking infection (neutralising antibodies, NAbs) of either specific viral strains or multiple viral strains (broadly-neutralising antibodies, bNAbs). More recently, a focus on non-neutralising antibodies (nNAbs), or neutralisation-independent effects of NAbs, has emerged...
April 3, 2024: Antibodies
https://read.qxmd.com/read/38650890/entry-inhibitors-as-arenavirus-antivirals
#4
REVIEW
Kruthika Iyer, Zhonghao Yan, Susan R Ross
Arenaviruses belonging to the Arenaviridae family, genus mammarenavirus, are enveloped, single-stranded RNA viruses primarily found in rodent species, that cause severe hemorrhagic fever in humans. With high mortality rates and limited treatment options, the search for effective antivirals is imperative. Current treatments, notably ribavirin and other nucleoside inhibitors, are only partially effective and have significant side effects. The high lethality and lack of treatment, coupled with the absence of vaccines for all but Junín virus, has led to the classification of these viruses as Category A pathogens by the Centers for Disease Control (CDC)...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38650887/spike-1-trimer-a-nanoparticle-vaccine-against-porcine-epidemic-diarrhea-virus-induces-protective-immunity-challenge-in-piglets
#5
JOURNAL ARTICLE
Linjie Li, Shuanghui Yin, Jingjing Zhou, Liping Zhang, Zhidong Teng, Lu Qiao, Yunhang Wang, Jiaxi Yu, Haoyue Zang, Yaozhong Ding, Xinsheng Liu, Shiqi Sun, Huichen Guo
Porcine epidemic diarrhea virus (PEDV) is considered the cause for porcine epidemic diarrhea (PED) outbreaks and hefty losses in pig farming. However, no effective commercial vaccines against PEDV mutant strains are available nowadays. Here, we constructed three native-like trimeric candidate nanovaccines, i.e., spike 1 trimer (S1-Trimer), collagenase equivalent domain trimer (COE-Trimer), and receptor-binding domain trimer (RBD-Trimer) for PEDV based on Trimer-Tag technology. And evaluated its physical properties and immune efficacy...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38650361/safety-immunogenicity-and-protective-effective-of-inhaled-covid-19-vaccines-a-systematic-review-and-meta-analysis
#6
REVIEW
Gao Song, Rong Li, Meng-Qun Cheng
This study aimed to examine the safety, immunogenicity and protective effective of inhaled COVID-19 vaccines (ICVs). Literature research was done through EMBASE, Cochrane, PubMed, and Web of Science up to 10 March 2024. Pooled estimates with corresponding 95% confidence intervals (CI) were computed and compared using the random effects and common effects model. Of the 15 studies, 11 analyzed safety, 13 analyzed immunogenicity, and 3 analyzed protective effective. The results showed a favorable safety profile of ICVs for primary vaccination series, however it does not always seem to produce the expected immune response and protective effective...
April 2024: Journal of Medical Virology
https://read.qxmd.com/read/38649824/characteristics-and-outcomes-of-covid-19-patients-presumed-to-be-treated-with-sotrovimab-in-nhs-hospitals-in-england
#7
JOURNAL ARTICLE
Vishal Patel, Bethany Levick, Stephen Boult, Daniel C Gibbons, Myriam Drysdale, Emily J Lloyd, Moushmi Singh, Helen J Birch
BACKGROUND: The impact of the constantly evolving severe acute respiratory syndrome coronavirus 2 on the effectiveness of early coronavirus disease 2019 (COVID-19) treatments is unclear. Here, we report characteristics and acute clinical outcomes of patients with COVID-19 treated with a monoclonal antibody (mAb; presumed to be sotrovimab) across six distinct periods covering the emergence and predominance of Omicron subvariants (BA.1, BA.2, and BA.5) in England. METHODS: Retrospective cohort study using data from the Hospital Episode Statistics database from January 1-July 31, 2022...
April 22, 2024: BMC Infectious Diseases
https://read.qxmd.com/read/38649782/author-correction-durability-of-neutralizing-rsv-antibodies-following-nirsevimab-administration-and-elicitation-of-the-natural-immune-response-to-rsv-infection-in-infants
#8
Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, Michael E Abram, Amanda Leach, Tonya Villafana, Mark T Esser
No abstract text is available yet for this article.
April 22, 2024: Nature Medicine
https://read.qxmd.com/read/38649079/structural-basis-for-the-recognition-of-ifnar1-by-the-humanized-therapeutic-monoclonal-antibody-qx006n-for-the-treatment-of-systemic-lupus-erythematosus
#9
JOURNAL ARTICLE
Xiaorong Chen, Huimin Ke, Wei Li, Lu Yin, Wei Chen, Tao Chen, Yiliang Wu, Jiwan Qiu, Wei Feng
Interferon (IFN) alpha/beta receptor 1 (IFNAR1) is indispensable for antiviral responses and the immune regulation. Dysregulation of the IFNAR1-mediaetd signaling pathways leads to deleterious autoimmune diseases such as systemic lupus erythematosus (SLE). QX006N, a humanized therapeutic monoclonal antibody, specifically targets human IFNAR1 and is in the clinical trial phase for treating SLE, but the molecular mechanism underlying the QX006N-mediated recognition of IFNAR1 remains unclear. Here, we report the high neutralization activities of QX006N against IFNAR1-mediated signal transduction...
April 20, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38649070/validation-of-a-severe-acute-respiratory-syndrome-coronavirus-2-microneutralization-assay-for-evaluation-of-vaccine-immunogenicity
#10
JOURNAL ARTICLE
Stephanie Hamilton, Mingzhu Zhu, Shane Cloney Clark, Penny Mayes, Jen Fenner, Leah Cui, Rongman Cai, Raj Kalkeri, Louis F Fries, Melinda Pryor, Joyce Plested
As variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, assessment of vaccine immunogenicity remains a critical factor to support continued vaccination. To this end, an in vitro microneutralization (MN50) assay was validated to quantitate SARS-CoV-2 neutralizing antibodies against prototype and variant strains (Beta, Delta, Omicron BA.1, Omicron BA.5, and XBB.1.5) in human serum. For the prototype strain, the MN50 assay met acceptance criteria for inter-/intra-assay precision, specificity, linearity, and selectivity...
April 20, 2024: Journal of Virological Methods
https://read.qxmd.com/read/38648957/cadherin-11-targeted-cell-specific-liposomes-enabled-skin-fibrosis-treatment-by-inducing-apoptosis
#11
JOURNAL ARTICLE
Himanshu N Bhatt, Rimpy Diwan, Igor L Estevao, Rui Dong, Jennifer Smith, Chuan Xiao, Sandeep K Agarwal, Md Nurunnabi
Continuous and aberrant activation of myofibroblasts is the hallmark of pathological fibrosis (e.g., abnormal wound healing). The deposition of excessive extracellular matrix (ECM) components alters or increases the stiffness of tissue and primarily accounts for multiple organ dysfunctions. Among various proteins, Cadherin-11 (CDH11) has been reported to be overexpressed on myofibroblasts in fibrotic tissues. Anti-apoptotic proteins such as (B cell lymphoma-2) (BCL-2) are also upregulated on myofibroblasts...
April 20, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38648648/evaluation-of-the-homogenous-mobility-shift-assay-for-infliximab-and-adalimumab-anti-drug-antibody-detection-in-the-clinical-laboratory
#12
JOURNAL ARTICLE
Paula Elizabeth Keating, Barry D Hock, Paul K L Chin, John Liston O'Donnell, Murray Lindsay Barclay
BACKGROUND: Detecting antidrug antibodies (ADAs) against infliximab or adalimumab is useful for therapeutic drug monitoring. Various ADA detection methods exist, and antibody titer is an output in some algorithms. Homogenous mobility shift assay (HMSA) measures relative ADA concentration and determines drug-ADA complex size in vitro. However, the relevance of complex size determination in drug monitoring remains unclear. Hence, the association between complex size, ADA concentration, and sample detectable neutralizing activity was evaluated...
April 9, 2024: Therapeutic Drug Monitoring
https://read.qxmd.com/read/38648230/live-attenuated-chikv-vaccine-with-rearranged-genome-replicates-in-vitro-and-induces-immune-response-in-mice
#13
JOURNAL ARTICLE
Irina Tretyakova, Joongho Joh, Mary Gearon, Jennifer Kraenzle, Sidney Goedeker, Ava Pignataro, Brian Alejandro, Igor S Lukashevich, Donghoon Chung, Peter Pushko
Chikungunya fever virus (CHIKV) is a mosquito-borne alphavirus that causes wide-spread human infections and epidemics in Asia, Africa and recently, in the Americas. CHIKV is considered a priority pathogen by CEPI and WHO. Despite recent approval of a live-attenuated CHIKV vaccine, development of additional vaccines is warranted due to the worldwide outbreaks of CHIKV. Previously, we developed immunization DNA (iDNA) plasmid capable of launching live-attenuated CHIKV vaccine in vivo. Here we report the use of CHIKV iDNA plasmid to prepare a novel, live-attenuated CHIKV vaccine V5040 with rearranged RNA genome...
April 22, 2024: PLoS Neglected Tropical Diseases
https://read.qxmd.com/read/38647550/suppression-of-type-i-interferon-signaling-in-myeloid-cells-by-autoantibodies-in-severe-covid-19-patients
#14
JOURNAL ARTICLE
Ami Aoki, Chiaki Iwamura, Masahiro Kiuchi, Kaori Tsuji, Atsushi Sasaki, Takahisa Hishiya, Rui Hirasawa, Kota Kokubo, Sachiko Kuriyama, Atsushi Onodera, Tadanaga Shimada, Tetsutaro Nagaoka, Satoru Ishikawa, Akira Kojima, Haruki Mito, Ryota Hase, Yasunori Kasahara, Naohide Kuriyama, Sukeyuki Nakamura, Takashi Urushibara, Satoru Kaneda, Seiichiro Sakao, Osamu Nishida, Kazuhisa Takahashi, Motoko Y Kimura, Shinichiro Motohashi, Hidetoshi Igari, Yuzuru Ikehara, Hiroshi Nakajima, Takuji Suzuki, Hideki Hanaoka, Taka-Aki Nakada, Toshiaki Kikuchi, Toshinori Nakayama, Koutaro Yokote, Kiyoshi Hirahara
PURPOSE: Auto-antibodies (auto-abs) to type I interferons (IFNs) have been identified in patients with life-threatening coronavirus disease 2019 (COVID-19), suggesting that the presence of auto-abs may be a risk factor for disease severity. We therefore investigated the mechanism underlying COVID-19 exacerbation induced by auto-abs to type I IFNs. METHODS: We evaluated plasma from 123 patients with COVID-19 to measure auto-abs to type I IFNs. We performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells from the patients with auto-abs and conducted epitope mapping of the auto-abs...
April 22, 2024: Journal of Clinical Immunology
https://read.qxmd.com/read/38647327/a-tetravalent-dengue-virus-like-particle-vaccine-induces-high-levels-of-neutralizing-antibodies-and-reduces-dengue-replication-in-non-human-primates
#15
JOURNAL ARTICLE
Daniel Thoresen, Kenta Matsuda, Akane Urakami, Mya Myat Ngwe Tun, Takushi Nomura, Meng Ling Moi, Yuri Watanabe, Momoko Ishikawa, Trang Thi Thu Hau, Hiroyuki Yamamoto, Yuriko Suzaki, Yasushi Ami, Jonathan F Smith, Tetsuro Matano, Kouichi Morita, Wataru Akahata
Dengue virus (DENV) represents a significant global health burden, with 50% of the world's population at risk of infection, and there is an urgent need for next-generation vaccines. Virus-like particle (VLP)-based vaccines, which mimic the antigenic structure of the virus but lack the viral genome, are an attractive approach. Here, we describe a dengue VLP (DENVLP) vaccine which generates a neutralizing antibody response against all four DENV serotypes in 100% of immunized non-human primates for up to 1 year...
April 22, 2024: Journal of Virology
https://read.qxmd.com/read/38646535/an-in-vitro-assay-for-toxicity-testing-of-clostridium-perfringens-type-c-%C3%AE-toxin
#16
JOURNAL ARTICLE
Marieke Hoonakker, Afshin Zariri, Lisette de Brouwer, Dionne David, Anouska Borgman, Arjen Sloots
INTRODUCTION: Veterinary vaccines against Clostridium perfringens type C need to be tested for absence of toxicity, as mandated by pharmacopoeias worldwide. This toxicity testing is required at multiple manufacturing steps and relies on outdated mouse tests that involve severe animal suffering. Clostridium perfringens type C produces several toxins of which the β-toxin is the primary component responsible for causing disease. Here, we describe the successful development of a new cell-based in vitro assay that can address the specific toxicity of the β-toxin...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38645492/liposomal-factor-viii-as-an-efficient-pharmaceutical-system-for-the-treatment-of-hemophilia
#17
JOURNAL ARTICLE
Maryam Karimi, Seyed Mahdi Rezayat, Seyed Alireza Mortazavi, Azadeh Haeri, Mahmoud Reza Jaafari
OBJECTIVES: Currently, the most important treatment approach for hemophilia type A is recombinant Factor VIII. However, due to its low retention time in the blood, the patients usually need successive injections. In addition, neutralization of injected proteins by antibodies complicates treatment. We examined the prolongation of the persistence time of injectable FVIII in the blood and the potential effects on survival using promising PEGylated liposomes (PEGLip) utilizing hydrogenated soy phosphatidylcholine (HSPC, Tm= 54...
2024: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/38645468/farnesol-and-selected-nanoparticles-silver-gold-copper-and-zinc-oxide-as-effective-agents-against-biofilms-formed-by-pathogenic-microorganisms
#18
JOURNAL ARTICLE
Agata Lange, Arkadiusz Matuszewski, Marta Kutwin, Agnieszka Ostrowska, Sławomir Jaworski
PURPOSE: Biofilms, which are created by most microorganisms, are known for their widely developed drug resistance, even more than planktonic forms of microorganisms. The aim of the study was to assess the effectiveness of agents composed of farnesol and nanoparticles (silver, gold, copper, and zinc oxide) in the degradation of biofilms produced by pathogenic microorganisms. METHODS: Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, Pseudomonas aeruginosa , and Candida albicans were used to create the biofilm structure...
2024: Nanotechnology, Science and Applications
https://read.qxmd.com/read/38645274/effects-of-n-glycans-on-the-structure-of-human-iga2
#19
JOURNAL ARTICLE
Valentina Ruocco, Clemens Grünwald-Gruber, Behzad Rad, Rupert Tscheliessnig, Michal Hammel, Richard Strasser
The transition of IgA antibodies into clinical development is crucial because they have the potential to create a new class of therapeutics with superior pathogen neutralization, cancer cell killing, and immunomodulation capacity compared to IgG. However, the biological role of IgA glycans in these processes needs to be better understood. This study provides a detailed biochemical, biophysical, and structural characterization of recombinant monomeric human IgA2, which varies in the amount/locations of attached glycans...
2024: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/38643858/amino-acid-substitution-of-the-membrane-proximal-external-region-alter-neutralization-sensitivity-in-a-chronic-hiv-1-clade-b-infected-patient
#20
JOURNAL ARTICLE
Yuyu Fu, Shuhui Wang, Yanling Hao, Dan Li, Li Ren, Zheng Wang, Ran Chen, Wenqi Tang, Xiuli Shen, Wanqi Ni, Yutao Shi, Meiling Zhu, Yiming Shao, Ying Liu
The membrane-proximal external region (MPER) represents a highly conserved region of the Human Immunodeficiency Virus (HIV) envelope glycoprotein (env) targeted by several broadly neutralizing antibodies (bnAbs). In this study, we employed single genome amplification to amplify 34 full-length env sequences from the 2005 plasma sample of CBJC504, a chronic HIV-1 clade B infected individual. We identified three amino acid changes (N671S, D674N, and K677R) in the MPER. A longitudinal analysis revealed that the proportion of env sequences with MPER mutations increased from 26...
April 19, 2024: Virus Research
keyword
keyword
75211
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.